Groundbreaking CAR T-Cell Therapy Cures Rare Autoimmune Trifecta
A woman in Germany, diagnosed with an extremely rare combination of three autoimmune diseases, has experienced no symptoms since receiving a single dose of engineered immune cells. The patient had previously undergone nine other types of treatment without improvement, leading to severe pain, fatigue, and an inability to work. Her condition was described as life-threatening.
After nine failed treatments and a life-threatening condition, a single dose of engineered immune cells brought complete remission.
The Patient's Condition: A Life-Threatening Trifecta
The patient suffered from a trifecta of autoimmune diseases, all stemming from problematic B cells, a type of immune cell. These B cells produced antibodies that mistakenly attacked her own tissues:
- Autoimmune haemolytic anaemia: Antibodies attacked red blood cells, requiring frequent transfusions.
- Immune thrombocytopenia: Antibodies attacked platelets, increasing bleeding risk.
- Antiphospholipid syndrome: Antibodies attacked fat-binding proteins, increasing blood clotting risk.
This combination of diseases is considered highly dangerous, with typical treatments involving long-term, high-dose steroids. These steroids broadly suppress the immune system and increase infection risks. However, traditional treatments failed to control her severe symptoms.
CAR T-Cell Treatment: A Breakthrough Solution
The patient was referred to University Hospital Erlangen in Germany, known for its pioneering work with chimeric antigen receptor (CAR) T cells for single-dose treatments. CAR T cells are the recipient's own T cells, engineered to specifically target and eliminate certain cells.
In this case, the patient's T cells were engineered to attack a protein found exclusively on B cells. Within one month of receiving the CAR T-cell treatment, alongside two chemotherapy drugs designed to kill fast-dividing immune cells, the woman achieved normal levels of red blood cells and has remained symptom-free. These living CAR T cells can be effective for years post-infusion.